Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS - Get Free Report) traded down 7.4% during trading on Thursday. The stock traded as low as $11.34 and last traded at $11.1190. 251,251 shares changed hands during trading, a decline of 57% from the average daily volume of 585,250 shares. The stock had previously closed at $12.01.
Analyst Upgrades and Downgrades
Several research analysts recently weighed in on the stock. Benchmark reaffirmed a "buy" rating on shares of Alpha Tau Medical in a report on Thursday, July 23rd. Piper Sandler raised Alpha Tau Medical from a "neutral" rating to an "overweight" rating and upped their price objective for the stock from $8.00 to $22.00 in a research note on Wednesday, November 11th. Zacks Research raised Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a research note on Monday, November 9th. UBS Group reiterated a "buy" rating on shares of Alpha Tau Medical in a research report on Tuesday. Finally, Barclays upped their target price on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, September 3rd. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $18.20.
Read Our Latest Stock Analysis on DRTS
Alpha Tau Medical Price Performance
The company has a current ratio of 11.09, a quick ratio of 7.79 and a debt-to-equity ratio of 0.15. The firm's 50-day moving average price is $13.90 and its 200-day moving average price is $10.99. The stock has a market capitalization of $1.02 billion, a PE ratio of -10.85 and a beta of 1.28.
Insider Activity at Alpha Tau Medical
In other news, CFO Raphi Levy sold 2,871 shares of the business's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $15.00, for a total transaction of $43,065.00. Following the transaction, the chief financial officer owned 90,180 shares of the company's stock, valued at approximately $1,352,700. The trade was a 3.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 39.50% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Everhart Financial Group Inc. bought a new stake in shares of Alpha Tau Medical in the 2nd quarter worth about $126,000. Renaissance Technologies LLC bought a new position in Alpha Tau Medical during the 1st quarter valued at about $286,000. Finally, Principal Financial Group Inc. purchased a new stake in Alpha Tau Medical in the 1st quarter worth about $132,000. Institutional investors own 2.65% of the company's stock.
About Alpha Tau Medical
(
Get Free Report)
Alpha Tau Medical Ltd. is an Israel-based medical technology company developing Alpha DaRT, an investigational radiation treatment for solid tumors. The company was founded in 2016 and is headquartered in Jerusalem. Alpha DaRT uses tiny sources containing radium-224 that are placed directly inside a tumor. As the material decays, it releases alpha-emitting atoms that travel a short distance through the tumor, aiming to destroy cancer cells while limiting exposure to nearby healthy tissue. The company is conducting clinical development of Alpha DaRT for multiple types of solid tumors, with research and clinical trials in Israel and other countries, including the United States and Japan.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alpha Tau Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Tau Medical wasn't on the list.
While Alpha Tau Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.